1. Senesco: Clinical Success with Multiple Myeloma

Strange, but welcome news in Senesco Technologies (SNT AMEX) this week. Almost all the news for the past two weeks has been good but he shares do not reflect this news.

On Monday the company announced the results of its pre-clinical trials of its cancer therapy with Celgene’s lenalidomide in which tumor growth in mice had been stabilized and in several cases reversed. Two weeks ago (July 27th) the company announced that the drug, SNST-01 had been granted “orphan drug “status by the FDA for two additional blood cancers, mantle cell and diffuse large B-cell lymphomas. See our Morning Note of Friday July 27, 2012. This will ease clinical trials and increase funding potential for the company.

Written by Michael A. Berry, Ph.D. - [ Discovery Investing Web Site ]